Modern Express News (Reporter Gu Wei) On November 13, the "Guidelines for Clinical Practice of Hypertension" (hereinafter referred to as the "Guidelines") jointly formulated by academic institutions such as National Cardiovascular Disease Center , Chinese Medical Association , and the Cardiovascular Branch of the Chinese Medical Association were officially promulgated, in which the diagnostic criteria for hypertension were downgraded from ≥140/90mmHg to ≥130/80mmHg. What impact will this standard downgrade have on relevant pharmaceutical and medical companies? On November 14, the A-share pharmaceutical and medical sector rose sharply, including Yuyue Medical , Kefu Medical, and other products involving antihypertensive drugs, including Jiber, Tianyu Shares, and Xinlitai , which have risen sharply. However, some listed companies said that the impact of the downward adjustment of hypertension diagnostic standards is still difficult to predict in the short term and it will take time to observe.
"Surge" in patients with hypertension?
With the downward adjustment of the diagnostic criteria for hypertension, it means that the population in the range of 130/80mmHg~140/90mmHg will be transferred from the "normal high-value" population to the hypertensive population, and the number of hypertensive patients may increase significantly. It is reported that Sun Yingxian, director of the Department of Cardiovascular Medicine at the First Affiliated Hospital of , calculated that based on the 2011 data from the China Health and Nutrition Survey (CHNS), it is estimated that 613 million adult hypertension patients in China are estimated to meet the 2010 China Guidelines, and the number of people who meet the 2010 China Guidelines is about 268 million. This means that more than 300 million patients with hypertension may be "added" under the new standards.
Does this mean that the use of antihypertensive drugs will increase significantly? Liu Weiqi, executive director of the Sullivan Greater China medical team, told the Modern Express reporter that after the standards change, the number of patients diagnosed with hypertension will have a huge increase. With the popularization of concepts such as health management and early treatment, people with sub-health status will pay more attention to their own health, which may stimulate these new groups to start taking medication. For major pharmaceutical companies, these groups will be the target group that can make up for the reduction in income after the centralized procurement price reduction.
Liu Weiqi introduced that hypertensive drugs mainly include calcium antagonists, renin-angiotensin-aldosterone system inhibitors, adrenaline receptor blockers, compound antihypertensive drugs, diuretics, and sympathetic nerve inhibitors. The market size is huge, nearly 100 billion yuan before the centralized procurement. As the list of centralized procurement expanded, the market overall shrank, but it has rebounded and has grown slowly. The main manufacturers include Pfizer , Novartis , Stone Medicine , China Resources , etc. At present, surgical treatment of hypertension is still in the early stages. Renal arterial desympathetic ablation (RDN) may become a new technology for new treatment methods for hypertensive patients, but its effectiveness, safety, applicable population, and long-term health benefits will still require longer clinical research and confirmation.
Previously, Sullivan data predicted that China's anti-hypertensive drug market will reach RMB 114.9 billion in 2022. The "2021 Overview of the Treatment Drugs Industry of Primary Hypertension in China" released by Toubao Research Institute shows that about 95% of hypertension belong to primary hypertension and requires long-term medication treatment. The average annual compound growth rate of the market size of primary hypertension drugs in China from 2013 to 2019 reached 11.7%, and the scale in 2019 reached 84.08 billion yuan. In the future, the market size of China's primary hypertensive drugs will continue to expand, but the growth rate will slow down. It is expected that the market size will reach nearly 154.701 billion yuan by 2026.
" Hypertension is not only the chronic disease with the largest number of patients, but also the most important risk factor for death by cardiovascular and cerebrovascular disease. In fact, some countries around the world have previously lowered the threshold for diagnosis of hypertension from 140/90mmHg to 130/80mmHg." A relevant person in charge of Yuyue Medical Blood Pressure Monitor said, "The release of my country's new version of the "Guidelines" means that clinical attention should be paid to blood pressure management, and advocated moving the defense line of hypertension forward, strengthening blood pressure reduction, simplifying the stratification of cardiovascular risk, and paying attention to secondary hypertension screening."
Many listed companies responded to
△ Tianyu Co., Ltd.'s anti-hypertensive raw materials and intermediate business revenue According to Tonghuashun ifind
111, the A-share pharmaceutical and medical sector rose overall, and sub-sectors such as traditional Chinese medicine, pharmaceutical business, and new crown drugs rose sharply. The stock prices of related listed companies involving anti-hypertensive drugs and blood pressure monitor products also rose sharply. Kefu Medical rose 14%, Jibel rose 13.19%, Yuyue Medical hit the daily limit , and Tianyu Co., Ltd. rose 8.67%. However, the relevant companies said that it is difficult to judge the direct reason for the rise in stock prices.
A Among listed companies, Yuyue Medical, Kefu Medical, Jiuan Medical , Lexin Medical and other companies have blood sphygmomanomics related products. This year's Double Eleven data shows that Yuyue Medical sphygmomanomics has the highest sales volume in Tmall and JD . The company's 2022 semi-annual report stated that in recent years, the awareness, treatment rate and control rate of hypertension among Chinese residents have been significantly improved, but there is still a big gap in more developed market countries. The continuous increase in the prevalence of hypertension and the continuous increase in the detection awareness of blood pressure has driven the continuous expansion of market demand, and the prospects for related businesses are broad. After the reduction of the
" threshold, it will have two impacts: for ordinary people, they may pay more attention to home blood pressure detection management; for the industry, the demand for smart blood sphygmomanomics will increase. Because blood pressure is proportional to age and the threshold is lowered, the age group of hypertensive patients will also decrease, which means that more young and middle-aged people need blood pressure testing, and these groups are more inclined to manage blood pressure through apps, mini programs, and smart devices. "The person in charge of the above-mentioned Yuyue Medical Blood Pressure Monitor told the Modern Express reporter.
semi-annual report shows that in the first half of this year, Yuyue Medical's household electronic testing and in vitro diagnostic products achieved revenue of approximately 810 million yuan, increased by 7.38% year-on-year, and gross profit margin was 47.13%.
involves antihypertensive drugs A The listed companies mainly include Jiber, Xinlitai, Tianyu Co., Ltd., Huahai Pharmaceutical, Hengrui Pharmaceutical , etc. Among them, Tianyu Co., Ltd. is one of the largest and most complete sartan antihypertensive drug raw materials and intermediates production companies in the world. Sartan drugs have thorough antihypertensive effects, few side effects, long-term efficacy and can be used in conjunction with other sartan drugs. It has become the most widely used hypertensive therapeutic drug. Tianyu Co., Ltd. currently has the production capacity of various antihypertensive drug raw materials and intermediates such as valsartan , irbesartan , losartan potassium , candesartan oleatan, olmesartan oleatan.
In the first half of this year, Tianyu Co., Ltd. achieved revenue of 1.474 billion yuan, a year-on-year increase of 7.81%, among which the revenue of lowering blood pressure raw materials and intermediates reached 1.098 billion yuan, a year-on-year increase of 15.76%. Yang Peng, a securities representative of the company, told the Modern Express reporter that in the short term, the downgrade of the diagnostic standards of hypertension will not have any impact on the company, but it will definitely be a good thing in the long term.
, one of the main products of Jiber, Jiangsu listed company, is the first new compound anti-hypertensive drug in China, used to treat mild and moderate primary hypertension. Relevant persons of the company told reporters that they have also paid attention to reports on the downgrade of the diagnostic standards of hypertension, but at present, the impact on the company and the industry is still not yet discussed, and it still needs time to observe further. However, for anti-hypertensive drugs such as Nicole tablets, the company is further increasing its market promotion efforts.
link:
In fact, since the National Healthcare Security Administration organized centralized volume procurement of drugs in 2019, the domestic hypertensive drug market has entered the market. " "As for the common antihypertensive drug Valsartan after centralized procurement, each tablet was only 0.1 yuan, and amlodipine tablets were also as low as 0.07 yuan per tablet.
In addition, medical insurance negotiations have also promoted win-win results in clinical and industrial ends. Taking the newly added hypertensive drug alisartan (Xinlitan), which was added to the medical insurance negotiations in 2017, as an example, it was included in the medical insurance drug catalog for the first time in 2017. Xinlitai's sales and sales volume of this drug have ushered in rapid growth; in 2021, the payment price for renewing the contract through negotiations in the national medical insurance catalog was 4.3 yuan (240mg/plate). (Source: Chengdu Business Daily)
(Editor Wang Peng)
